Cingulate Inc Total Liabilities
Cingulate Inc total liabilities. Based on the latest financial reports, Cingulate Inc (CING) has total liabilities worth $12.56 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Cingulate Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cingulate Inc (2019–2025)
Total liabilities of Cingulate Inc from 2019 to 2025. This chart illustrates how Cingulate Inc's total liabilities have evolved over time, based on quarterly financial data.
Cingulate Inc Competitors by Total Liabilities
The table below lists competitors of Cingulate Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Menderes Tekstil Sanayi ve Ticaret AS
IS:MNDRS
|
Turkey | TL7.41 Billion |
|
Young Heung I&
KO:012160
|
Korea | ₩235.50 Billion |
|
Inta Bina Group Bhd
KLSE:0192
|
Malaysia | RM431.27 Million |
|
iNtRON Biotechnology Inc
KQ:048530
|
Korea | ₩4.73 Billion |
|
Hyperfine Inc
NASDAQ:HYPR
|
USA | $14.26 Million |
|
ConvaTec Group PLC
LSE:CTEC
|
UK | GBX1.96 Billion |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs161.00 Million |
|
Thermaltake Technology Co Ltd
TWO:3540
|
Taiwan | NT$4.03 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Cingulate Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Cingulate Inc.
Liquidity & Leverage Metrics
Cingulate Inc Total Liabilities Ratios Explained
Cingulate Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cingulate Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cingulate Inc (2019–2025)
The table below shows the annual total liabilities of Cingulate Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.56 Million | +69.58% |
| 2024-12-31 | $7.41 Million | -28.49% |
| 2023-12-31 | $10.36 Million | +37.72% |
| 2022-12-31 | $7.52 Million | +268.29% |
| 2021-12-31 | $2.04 Million | -54.56% |
| 2020-12-31 | $4.50 Million | -3.64% |
| 2019-12-31 | $4.66 Million | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more